甘精胰岛素和诺和灵30R对老年2型糖尿病的疗效

摘要

目的 评价甘精胰岛素或诺和灵30R联合瑞格列奈或阿卡波糖治疗老年2型糖尿病(T2DM)的疗效.方法 T2DM患者87例,年龄＞65岁,随机分为甘精胰岛素(A组,42例)和诺和灵30R(B组,45例),观察两组血糖控制情况及患者生存质量.结果 治疗第3个月时,A组的血糖达标率高于B组(P＜0.05),且前3个月空腹血糖变异系数(CV-FPG)低于B组(P＜0.05).治疗第12个月时A组生存质量评分明显高于B组(P＜0.05)；A组微血管-周围神经病变总体并发症的发病率明显低于B组(P＜0.05).结论 甘精胰岛素联合瑞格列奈或阿卡波糖治疗老年T2DM效果优于诺和灵30R.%Objective To compare the efficacy of insulin glargine and pre-mixed 30R plus oral antidiabetic drugs in the elderly with type 2 diabetes mellitus(T2DM). Methods A total of 87 T2DM patients aged >65 years old was treated with insulin glargine (group A, 42 cases) or pre-mixed 30R (group B,45 cases) combined with oral acarbose or repaglinide. The control of blood glucose(BG) and the quality of life(QL) were compared. Results After treated for 3 months, the rate of normal BG of group A was significantly higher than that of group B(P<0. 05). The first three months coefficient of variation of fasting BG in group A was significantly less than that in group B(P<0. 05). After treated for 12 months, the score of QL was higher, the incidence rate of complications in microvascular and peripheral neuropathy was lower,in group A than that in group B(P<0. 05). Conclusion Combined with oral acarbose or repaglinide, insulin glargine is better than pre-mixed 30R in treating T2DM in the elderly.